News

The trial aims to characterize the safety profile of NTx-428 when administered to patients who have sustained a TBI. The company expects to complete the recruitment of 10

Research and development expenses were $3.3m, compared to $1.1m for the same period in 2010, primarily related to the advancement of the Phase III clinical development program for

Patients eligible for this comparative study are previously treated with an anthracycline and a taxane during first-line therapy for metastatic disease. Phase 2 trial underlines Phase 1 eniluracil/5-FU/leucovorin

Vyvanse, a prescription medicine used for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), is administered orally as adjunctive therapy. Vyvanse was administered to 92 clinically stable patients with predominant

VEGF Trap-Eye, a human fusion protein and a highly potent blocker of the growth factors, is believed to decrease vascular permeability and edema and prevent the inappropriate growth

This is the 10th US patent issued to Dyadic adding to its portfolio of 74 international patents. The inventions exhibited by this patent relate to the use of

Biovista is a biotechnology company that profiles novel uses and side effects for existing drugs using their mechanism of action. Biovista president Aris Persidis said they look forward

Net profit increased by 23% to DKK4,073m. Gross margin improved by 0.3% in local currencies, reflecting a favorable product mix development, but due to a negative currency effect,

Acelot’s new technology searches and mines directly in the space of molecules; something that has been thought of as too complex and slow in the past. Acelot said